Cyclacel raises $1M via Series E convertible preferred stock; extends cash runway to Q3 2025

Bio Green Med Solution, Inc.

Gross proceeds of $1.0M from sale of 1M shares of Series E Convertible Preferred Stock at $1.00 per share.
Each Series E share convertible into 110 common shares, subject to stockholder approval per Nasdaq rules.
Offering closed on March 21, 2025; net proceeds for working capital and general corporate purposes.
Cash runway extended into third quarter 2025 based on current operating assumptions.
Securities sold under Regulation S exemption, no placement agent used.

item 3.02 item 1.01 item 3.03 item 5.03 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.